BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34091189)

  • 21. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
    Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
    Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma.
    Kang EJ; Ahn MJ; Ock CY; Lee KW; Kwon JH; Yang Y; Choi YH; Kim MK; Ji JH; Yun T; Nam BH; Kim SB; Keam B
    Clin Cancer Res; 2021 Oct; 27(19):5272-5279. PubMed ID: 34315722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
    Ho AL; Foster NR; Deraje Vasudeva S; Katabi N; Antonescu CR; Frenette GP; Pfister DG; Erlichman C; Schwartz GK
    Cancer; 2024 Mar; 130(5):702-712. PubMed ID: 37947157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck.
    de Haan LD; De Mulder PH; Vermorken JB; Schornagel JH; Vermey A; Verweij J
    Head Neck; 1992; 14(4):273-7. PubMed ID: 1381339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.
    Goncalves PH; Heilbrun LK; Barrett MT; Kummar S; Hansen AR; Siu LL; Piekarz RL; Sukari AW; Chao J; Pilat MJ; Smith DW; Casetta L; Boerner SA; Chen A; Lenkiewicz E; Malasi S; LoRusso PM
    Oncotarget; 2017 May; 8(20):32918-32929. PubMed ID: 28415633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma.
    Mahmood U; Bang A; Chen YH; Mak RH; Lorch JH; Hanna GJ; Nishino M; Manuszak C; Thrash EM; Severgnini M; Sanborn M; Sridharan V; Margalit DN; Tishler RB; Busse PM; Willers H; Mamon HJ; Yoo HJ; Pai SI; Wirth LJ; Haddad RI; Chau NG; Schoenfeld JD
    Int J Radiat Oncol Biol Phys; 2021 Jan; 109(1):134-144. PubMed ID: 32781104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.
    Locati LD; Cavalieri S; Bergamini C; Resteghini C; Alfieri S; Calareso G; Bossi P; Perrone F; Tamborini E; Quattrone P; Granata R; Galbiati D; Platini F; Orlandi E; Mariani L; Licitra L
    Head Neck; 2019 Oct; 41(10):3670-3676. PubMed ID: 31355973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
    Keam B; Kim SB; Shin SH; Cho BC; Lee KW; Kim MK; Yun HJ; Lee SH; Yoon DH; Bang YJ
    Cancer; 2015 Aug; 121(15):2612-7. PubMed ID: 25903089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial.
    Weiss GR; Liu PY; Alberts DS; Peng YM; Fisher E; Xu MJ; Scudder SA; Baker LH; Moore DF; Lippman SM
    Gynecol Oncol; 1998 Dec; 71(3):386-90. PubMed ID: 9887236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors.
    Hanna GJ; Stathis A; Lopez-Miranda E; Racca F; Quon D; Leyvraz S; Hess D; Keam B; Rodon J; Ahn MJ; Kim HR; Schneeweiss A; Ribera JM; DeAngelo D; Perez Garcia JM; Cortes J; Schönborn-Kellenberger O; Weber D; Pisa P; Bauer M; Beni L; Bobadilla M; Lehal R; Vigolo M; Vogl FD; Garralda E
    Cancer Res Commun; 2023 Sep; 3(9):1853-1861. PubMed ID: 37712875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
    Belhabri A; Thomas X; Wattel E; Chelghoum Y; Anglaret B; Vekhoff A; Reman O; Dombret H; Dhedin N; Michallet M; Fière D; Archimbaud E
    Hematol J; 2002; 3(1):49-55. PubMed ID: 11960396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma.
    Hanna GJ; Bae JE; Lorch JH; Schoenfeld JD; Margalit DN; Tishler RB; Haddad RI; Chau NG
    Oral Oncol; 2020 Jul; 106():104690. PubMed ID: 32283496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.
    Kanamaru A; Takemoto Y; Tanimoto M; Murakami H; Asou N; Kobayashi T; Kuriyama K; Ohmoto E; Sakamaki H; Tsubaki K
    Blood; 1995 Mar; 85(5):1202-6. PubMed ID: 7858250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
    Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
    Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma.
    Ferrarotto R; Sousa LG; Feng L; Mott F; Blumenschein G; Altan M; Bell D; Bonini F; Li K; Marques-Piubelli ML; Dal Lago EA; Johnson JJ; Mitani Y; Godoy M; Lee A; Kupferman M; Hanna E; Glisson BS; Elamin Y; El-Naggar A
    J Clin Oncol; 2023 May; 41(15):2843-2851. PubMed ID: 36898078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
    Rodriguez CP; Wu QV; Voutsinas J; Fromm JR; Jiang X; Pillarisetty VG; Lee SM; Santana-Davila R; Goulart B; Baik CS; Chow LQM; Eaton K; Martins R
    Clin Cancer Res; 2020 Feb; 26(4):837-845. PubMed ID: 31796519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma.
    Goldberg JS; Vargas M; Rosmarin AS; Milowsky MI; Papanicoloau N; Gudas LJ; Shelton G; Feit K; Petrylak D; Nanus DM
    Cancer; 2002 Sep; 95(6):1220-7. PubMed ID: 12216088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid.
    Tobita T; Takeshita A; Kitamura K; Ohnishi K; Yanagi M; Hiraoka A; Karasuno T; Takeuchi M; Miyawaki S; Ueda R; Naoe T; Ohno R
    Blood; 1997 Aug; 90(3):967-73. PubMed ID: 9242525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of all-trans-retinoic acid alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukaemia.
    Colović MD; Janković GM; Elezović I; Vidović A; Bila JS; Novak A; Babić D
    Med Oncol; 1997 Jun; 14(2):65-72. PubMed ID: 9330265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
    Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
    Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.